^
    1year
    Generation of a mutant SIRPa fusion protein with highly-improved affinity and favorable safety profile (AACR 2023)
    SCR9168 demonstrates the best-in-class potential among SIRPα mutein molecules. It elicits improved and dose-dependent efficacy in phagocytosis or tumor suppression combining with therapeutic antibodies, such as trastuzumab or cetuximab. Favorable safety profile with no phagocytosis of RBC or platelets in vitro as well as no hematological toxicity observation in cynomolgus monkeys allows broader dose range exploration in early clinical phase.
    Clinical
    |
    CD47 (CD47 Molecule) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD47 expression
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • SCR9168